Also, HTI 1090 a dual inhibitor of IDO1 and hepatic enzyme tryptophan 2,3‐dioxygenase (TDO) is currently in phase I trial for advanced solid tumours including HNSCC.74 This evidence concerns the gene IDO1 and head and neck squamous cell carcinoma.